DaVita (DVA) board, executives and insiders

Date	Insider	Type	Shares	Price	Value
Jul 31, 2026	Berkshire Hathaway Inc	Sale	182,980	$199.55	$36.5M
Jun 16, 2026	Javier Rodriguez Chief Executive Officer	Sale	39,407	$209.28	$8.2M
Jun 15, 2026	Kathleen Alyce Waters Chief Legal & Pub. Affairs Off	Sale	8,950	$207.84	$1.9M
Jun 15, 2026	Kathleen Alyce Waters Chief Legal & Pub. Affairs Off	Sale	6,455	$209.17	$1.4M
Jun 15, 2026	Javier Rodriguez Chief Executive Officer	Sale	30,000	$209.50	$6.3M
May 15, 2026	James O. Hearty Chief Compliance Officer	Sale	15,000	$193.98	$2.9M
May 12, 2026	David Paul Maughan Chief Operating Officer, DKC	Sale	13,456	$199.25	$2.7M
May 11, 2026	David Paul Maughan Chief Operating Officer, DKC	Sale	7,073	$199.15	$1.4M
May 7, 2026	Joel Ackerman CFO and Treasurer	Sale	51,471	$192.10	$9.9M
May 6, 2026	James O. Hearty Chief Compliance Officer	Sale	2,184	$174.87	$382K
May 1, 2026	Berkshire Hathaway Inc	Sale	1,220,376	$149.84	$182.9M
Jan 29, 2026	Warren E. Buffett	Sale	1,658,480	$120.56	$199.9M
Oct 27, 2025	Berkshire Hathaway Inc	Sale	401,514	$135.36	$54.3M
Jul 31, 2025	Berkshire Hathaway Inc	Sale	1,635,962	$140.61	$230.0M
Jul 23, 2025	James O. Hearty Chief Compliance Officer	Sale	2,351	$150.00	$353K
May 27, 2025	Warren E. Buffett	Sale	11,978	$140.18	$1.7M
May 27, 2025	Warren E. Buffett	Sale	19,330	$138.59	$2.7M
May 27, 2025	Warren E. Buffett	Sale	71,966	$139.56	$10.0M
May 23, 2025	Warren E. Buffett	Sale	27,172	$137.28	$3.7M
May 23, 2025	Warren E. Buffett	Sale	36,094	$138.19	$5.0M
May 23, 2025	Warren E. Buffett	Sale	800	$138.60	$111K
May 22, 2025	Warren E. Buffett	Sale	1,256	$139.88	$176K
May 22, 2025	Warren E. Buffett	Sale	31,404	$138.94	$4.4M
May 8, 2025	Berkshire Hathaway Inc	Sale	1,145,938	$147.11	$168.6M
Feb 19, 2025	Warren E. Buffett	Sale	65,482	$153.61	$10.1M

Board and executive changes

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

Sep 13, 2024
Chief Operating Officer Transition On September 9, 2024, DaVita Inc. (the “Company”) announced that David P. Maughan, Senior Vice President of the Company, has been appointed Chief Operating Officer, DaVita Kidney Care, effective September 15, 2024 (the “Effective Date”). Mr. Maughan will replace Michael D. Staffieri, who will transition to the role of Chief Operating Officer Emeritus, as of the Effective Date. Mr. Maughan, 47, served as a Senior Vice President, Kidney Care, responsible for DaVita’s national home and hospital services businesses, as well as a range of key business functions including oversight of human resources, IT, marketing and communications, and State government affairs from November 2019 to September 2024. He joined DaVita in 2006 and served in various field operations roles of increasing responsibility from September 2006 to November 2019.
Read the 8-K filing
Apr 10, 2024
On April 6, 2024, the Board of Directors (the "Board") of DaVita Inc. (the "Company") adopted resolutions expanding the size of the Board from ten to eleven members, and appointing Dennis W. Pullin as a member of the Board, in each case effective as of April 10, 2024. The Board also appointed Mr. Pullin to serve as a member of the Compliance and Quality Committee of the Board, effective as of April 10, 2024. Mr. Pullin will receive the standard compensation and indemnification applicable to all other non-employee directors. The Company has described its Non-Employee Director Compensation Policy in the Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 25, 2023. The Company has entered into its standard indemnification agreement with Mr.
Read the 8-K filing
Jul 25, 2023
On July 19, 2023, DaVita Inc. (the “Company”) entered into an offer of employment (the “Offer Letter”) with Christopher Berry to become the Company’s Chief Accounting Officer. Pursuant to the Offer Letter, Mr. Berry will join the Company as Group Vice President, Accounting on August 28, 2023 (the “Effective Date”) and will succeed John D. Winstel in the role of Chief Accounting Officer when Mr. Winstel steps down from the role, no later than September 5, 2023. Mr. Berry, 48, will join the Company after holding the positions of Senior Vice President and Chief Accounting Officer at Sonder Holdings Inc. (“Sonder”), a publicly traded hospitality company, from August 2022 to August 2023. He also previously served as Sonder’s Interim Principal Financial Officer from January 2023 to March 2023. Prior to joining Sonder, Mr.
Read the 8-K filing
Jul 13, 2023
On July 12, 2023, the Board of Directors (the "Board") of DaVita Inc. (the "Company") adopted resolutions expanding the size of the Board from nine to ten members and appointing Wendy L. Schoppert as a member of the Board, in each case effective as of July 14, 2023. The Board also appointed Ms. Schoppert to serve as a member of the Audit Committee and the Compliance and Quality Committee of the Board, each effective as of July 14, 2023. Ms. Schoppert will receive the standard compensation and indemnification applicable to all other non-employee directors. The Company has described its Non-Employee Director Compensation Policy in the Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 25, 2023. The Company expects to enter into its standard indemnification agreement with Ms.
Read the 8-K filing
Mar 21, 2023
On March 15, 2023, John Winstel, Chief Accounting Officer of DaVita Inc. (the “Company”) notified the Company of his decision to step down from his position, with an expected transition period to end no later than September 5, 2023 (the “Effective Date”). The decision was not as a result of any disagreement with the Company or its independent registered public accounting firm on any matter relating to the Company’s financial or accounting operations, policies or practices or otherwise. Mr. Winstel is planning to continue in his role through the Effective Date, or until a successor is named by the Company, if earlier. The Company has commenced a search process for Mr. Winstel’s successor.
Read the 8-K filing
Sep 13, 2022
On September 8, 2022, the Board of Directors (the "Board") of DaVita Inc. (the "Company") adopted resolutions expanding the size of the Board from nine to ten members, and appointed Adam H. Schechter as a member of the Board, in each case effective as of September 20, 2022. The Board also appointed Mr. Schechter to serve as a member of the Audit Committee and Compliance and Quality Committee of the Board, each effective as of September 20, 2022. Mr. Schechter will receive the standard compensation and indemnification applicable to all other non-employee directors. We have described our Non-Employee Director Compensation Policy in our Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 25, 2022. The Company expects to enter into its standard indemnification agreement with Mr.
Read the 8-K filing
Apr 8, 2022
On April 6, 2022, the Board of Directors (the "Board") of DaVita Inc. (the "Company") adopted resolutions expanding the size of the Board from nine to ten members, and appointed Jason M. Hollar as a member of the Board, in each case effective as of May 6, 2022. The Board also appointed Mr. Hollar to serve as a member of the Audit Committee of the Board effective as of May 6, 2022. Mr. Hollar will receive the standard compensation and indemnification applicable to all other non-employee directors. We have described our Non-Employee Director Compensation Policy in our Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 23, 2021. The Company expects to enter into its standard indemnification agreement with Mr. Hollar, the form of which is an exhibit to our Current Report on Form 8-K filed with the SEC on December 20, 2006.
Read the 8-K filing
Sep 9, 2021
On September 9, 2021, the Board of Directors (the “Board”) of DaVita Inc. (the “Company”) adopted resolutions expanding the size of the Board from eight to nine members, and appointed Gregory J. Moore, M.D., Ph.D. as a member of the Board, to fill the newly created vacancy on the Board, in each case effective as of September 9, 2021. The Board also appointed Dr. Moore to serve as a member of the Nominating and Governance Committee and Compliance and Quality Committee of the Board effective as of September 9, 2021. Dr. Moore will receive the standard compensation and indemnification applicable to all other non-employee directors. We have described our Non-Employee Director Compensation Policy in our Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 23, 2021. The form of indemnification agreement we entered into with Dr.
Read the 8-K filing
May 21, 2021
On May 19, 2021, Shawn Guertin, member of the Board of Directors (the "Board") of DaVita Inc. (the "Company"), notified the Board that he will step down from the Board, as a member and chair of the Audit Committee of the Board (the "Audit Committee") and as a member of the Nominating and Governance Committee of the Board (the "Nominating and Governance Committee") due to anticipated increased time commitments associated with his pending new position as executive vice president and chief financial officer of CVS Health. Mr. Guertin therefore will no longer be considered a director nominee for the purposes of the election of directors at the Company's 2021 Annual Meeting of Stockholders to be held on June 10, 2021. Mr. Guertin's decision to step down is not the result of any disagreement with the Company and was effective as of May 19, 2021.
Read the 8-K filing
Dec 10, 2020
On December 9, 2020, Pascal Desroches, member of the Board of Directors (the "Board") of DaVita Inc. (the "Company"), notified the Board that he will step down from the Board, as a member and chair of the Audit Committee of the Board (the "Audit Committee") and as a member of the Compensation Committee of the Board due to increased time commitments associated with his pending new position as senior executive vice president and chief financial officer of AT&T Inc. Mr. Desroches' decision to step down is not the result of any disagreement with the Company and will be effective as of December 15, 2020. In connection with the foregoing, the Board approved a reduction in the size of the Board from 10 to 9 members and appointed Shawn M.
Read the 8-K filing
Oct 5, 2020
On October 5, 2020, DaVita Inc. (the “Company”) and Ms. LeAnne M. Zumwalt, the Company’s Group Vice President, Government Affairs, announced her retirement from DaVita Inc. after over twenty years of service. In connection with this announced retirement, Ms. Zumwalt entered into a Transition Agreement on October 1, 2020 (the “Transition Agreement”). Under the terms of the Transition Agreement, Ms. Zumwalt will serve as Group Vice President, Government Affairs until January 31, 2021 (the “Retirement Date”). Subject to Ms. Zumwalt’s continuous employment with the Company through the Retirement Date and execution and non-revocation of a release of claims in favor of the Company, (i) Ms.
Read the 8-K filing
Sep 8, 2020
On September 7, 2020, the Board of Directors (the “Board”) of DaVita Inc. (the “Company”) adopted resolutions expanding the size of the Board from nine to ten members, and appointed Shawn M. Guertin as a member of the Board, to fill the newly created vacancy on the Board, in each case effective as of September 15, 2020. The Board also appointed Mr. Guertin to serve as a member of the Audit Committee of the Board effective as of September 15, 2020. Mr. Guertin will receive the standard compensation and indemnification applicable to all other non-employee directors. We have described our Non-Employee Director Compensation Policy in our Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 27, 2020. The form of indemnification agreement we entered into with Mr.
Read the 8-K filing
Aug 11, 2020
On August 10, 2020, the Board of Directors (the “Board”) of DaVita Inc. (the “Company”) adopted resolutions expanding the size of the Board from eight to nine members, and appointed Paula A. Price as a member of the Board, to fill the newly created vacancy on the Board, in each case effective as of September 1, 2020. The Board also appointed Ms. Price to serve as a member of the Audit Committee of the Board effective as of September 1, 2020. Ms. Price will receive the standard compensation and indemnification applicable to all other non-employee directors. We have described our Non-Employee Director Compensation Policy in our Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 27, 2020. The form of indemnification agreement we entered into with Ms.
Read the 8-K filing
Jun 17, 2020
DaVita Inc. 2020 Incentive Award Plan On June 11, 2020, DaVita Inc. (the “Company”) held its virtual 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”). As described in
Read the 8-K filing
Mar 16, 2020
As previously announced, the term of Kent J. Thiry's Executive Chairman Agreement (the "Agreement") expires effective June 1, 2020. Accordingly, pursuant to the terms of the Agreement, Mr. Thiry will step down as Executive Chairman and a member of the Board of Directors (the "Board") of DaVita Inc. (the "Company") effective on June 1, 2020. Also as previously announced, Peter T. Grauer, the Company’s lead independent director since May 2003, plans to retire from the Board and therefore will not stand for re-election at the Company’s 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”). He also has decided to step down from the role of lead independent director effective June 1, 2020, and plans to serve as a director of the Company until the expiration of his current term. In connection with the foregoing, on March 11, 2020, the Board appointed Pamela M.
Read the 8-K filing

Show 11 older changes

Jan 24, 2020
On January 23, 2020, DaVita Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”) to vote upon a proposed amendment (the “Proposed Plan Amendment”) to the Company’s 2011 Incentive Award Plan (the “Plan”) to lift the Plan provision that limits to 2,250,000 the number of shares of the Company’s common stock (the “Common Stock”) that may be subject to awards made to any one person during any consecutive twelve-month period, so as to allow for a grant of a one-time award of 2,500,000 premium-priced stock-settled appreciation rights (the “Premium-Priced SSAR Award”) to the Company’s Chief Executive Officer. As described in
Read the 8-K filing
Nov 5, 2019
On November 5, 2019, Peter Grauer, a member of the Board of Directors (the “Board”) of the Company since 1994 and the Company’s lead independent director since 2003, notified the Board that he plans to retire from the Board and therefore will not stand for re-election at the Company’s 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”). Mr. Grauer conveyed that he believes it is an appropriate time for him to retire from the Board in light of the Company’s completion of its Chief Executive Officer transition effective June 1, 2019, and the sale of its DaVita Medical Group division on June 19, 2019. Mr. Grauer has indicated his intention to continue to serve as a director of the Company until the expiration of his current term at the 2020 Annual Meeting and that his decision not to stand for re-election at the Annual Meeting was not due to any disagreement with the Company.
Read the 8-K filing
Oct 29, 2019
On October 28, 2019, DaVita Inc. (the “Company”) announced that John Winstel will become the Company’s Chief Accounting Officer. Mr. Winstel joined the Company as Group Vice President, Accounting on October 28, 2019 (the “Effective Date”), and will succeed James K. Hilger in the role of Chief Accounting Officer no later than March 3, 2020. As previously disclosed, Mr. Hilger entered into a Transition Agreement with the Company on July 31, 2018, relating to his retirement from the Company. Accordingly, Mr. Hilger will step down from his position as the Company’s Chief Accounting Officer upon Mr. Winstel’s transition to the Chief Accounting Officer role. Mr.
Read the 8-K filing
Apr 29, 2019
Executive Transition On April 27, 2019, the Board of Directors (the “Board”) of DaVita Inc. (the “Company”) appointed Javier J. Rodriguez, currently Chief Executive Officer of DaVita Kidney Care, as Chief Executive Officer of the Company and a director, effective June 1, 2019 (the “Effective Date”). Mr. Rodriguez will replace Kent J. Thiry, who will step down as Chairman of the Board and Chief Executive Officer of the Company and DaVita Medical Group and will assume the position of Executive Chairman of the Board as of the Effective Date. Mr. Rodriguez, 48, joined the Company in 1998 and has served the Company in a number of different capacities. He has served as Chief Executive Officer of DaVita Kidney Care since March 2014 and, prior to this, served as the Company’s president from February 2012 to March 2014. Employment Agreement with Mr.
Read the 8-K filing
Aug 23, 2018
Amendment to Employment Agreement DaVita Inc. (the “Company”) entered into an amendment (the “Amendment”) to the employment agreement with Kent J. Thiry, the Company’s Chairman and Chief Executive Officer and the Chief Executive Officer of DaVita Medical Group, effective as of August 20, 2018. The Amendment removes the additional payment that Mr. Thiry would be eligible to receive for excise taxes incurred under Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”), and replaces such provision with a provision that automatically reduces any payments or benefits related to a change in control of the Company to the extent necessary to avoid the imposition of excise taxes under Section 4999 of the Code, provided that such reduction would result in a better after-tax result for Mr. Thiry.
Read the 8-K filing
Feb 7, 2018
(b) On February 1, 2018, Carol Anthony (John) Davidson, a member of the Board of Directors (the “Board”) of DaVita Inc. (the “Company”) since 2010, notified the Company that he plans to retire from the Board on March 1, 2018. Mr. Davidson’s decision to retire was not due to any disagreement with the Company. Also on February 1, 2018, the Board adopted resolutions that provide that the size of the Board will be reduced from eleven to ten members, effective upon Mr. Davidson’s retirement.
Read the 8-K filing
Apr 3, 2017
(b) On March 29, 2017, Roger J. Valine, a member of the Board of Directors (the “Board”) of DaVita Inc. (the “Company”) since 2006, notified the Board that he plans to retire from the Board and therefore will not stand for re-election at the Company’s 2017 Annual Meeting of Stockholders to be held in June 2017 (the “2017 Annual Meeting”). Mr. Valine has indicated his intention to continue to serve as a director of the Company until the expiration of his current term at the 2017 Annual Meeting. Mr. Valine’s decision not to stand for re-election at the Annual Meeting was not due to any disagreement with the Company.
Read the 8-K filing
Jan 5, 2017
On January 5, 2017, the Board of Directors (the “Board”) of DaVita Inc. (the “Company”) adopted resolutions expanding the Board from 11 to 12 members, and appointed Pascal Desroches, as a member of the Board, to fill the newly created seat on the Board. Mr. Desroches will receive the standard compensation and indemnification applicable to all other non-employee directors. We have described our Non-Employee Director Compensation Policy in our Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 10, 2016. The form of indemnification agreement we entered into with Mr. Desroches is an exhibit to our Current Report on Form 8-K filed with the SEC on December 20, 2006. No arrangement or understanding exists between Mr. Desroches and any other person or persons pursuant to which he was selected as a director.
Read the 8-K filing
Jan 5, 2017
On January 5, 2017, DaVita Inc. (the “Company”) appointed Joel Ackerman, who will join the Company and become its Chief Financial Officer. Mr. Ackerman will initially serve in the position of Senior Vice President, Finance beginning on or about February 21, 2017 and continuing until the day after the Company files its Annual Report on Form 10-K for the year ended December 31, 2016, at which time he will become Chief Financial Officer. Jim Hilger has served as the Interim Chief Financial Officer since March 2015. He will continue in his role as Chief Accounting Officer, a position he has held since April 2010, when Mr. Ackerman becomes Chief Financial Officer. Prior to joining the Company, Mr.
Read the 8-K filing
Oct 20, 2016
On October 17, 2016, Dennis L. Kogod and DaVita Inc. (the “Company”) entered into a separation agreement (the “Agreement”) in connection with Mr. Kogod’s termination of employment with the Company, effective November 30, 2016. The Agreement provides for the end of Mr. Kogod’s employment and for his resignation from other non-employment roles with the Company and its subsidiaries, his consulting services to the Company for three years pursuant to a separate consulting agreement (the “Consulting Agreement”), and a release of the Company and certain affiliates from claims, in return for which the Company agreed to pay him $1,500,000. Under the Consulting Agreement Mr.
Read the 8-K filing
Jul 13, 2016
On July 11, 2016, the Board of Directors (the “Board”) of DaVita HealthCare Partners Inc. (the “Company”) adopted resolutions expanding the Board from 10 to 11 members, and appointed Phyllis R. Yale, as a member of the Board, to fill the newly created seat on the Board. A copy of the press release announcing the appointment of Ms. Yale is attached hereto as Exhibit 99.1. Ms. Yale will receive the standard compensation and indemnification applicable to all other non-employee directors. We have described our Non-Employee Director Compensation Policy in our Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 10, 2016. The form of indemnification agreement we entered into with Ms. Yale is an exhibit to our Current Report on Form 8-K filed with the SEC on December 20, 2006. No arrangement or understanding exists between Ms.
Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

Share price

$191.35+183% since 2016 board/officer change filed

Annual financials

From the company's 10-K XBRL data (SEC companyfacts).

Fiscal year	Revenue	Net income	Margin	Diluted EPS	Total assets
FY2025	$13.6B	$746.8M	5.5%	$9.84	$17.5B
FY2024	$12.8B	$936.3M	7.3%	$10.73	$17.3B
FY2023	$12.1B	$691.5M	5.7%	$7.42	$16.9B
FY2022	$11.6B	$560.4M	4.8%	$5.85	$16.9B
FY2021	$11.6B	$978.5M	8.4%	$8.90	$17.1B
FY2020	$11.6B	$773.6M	6.7%	$6.31	$17.0B
FY2019	$11.4B	$811.0M	7.1%	$5.27	$17.3B
FY2018	$11.4B	$159.4M	1.4%	$0.92	$19.1B